IDH野生型惰性弥漫性胶质瘤的临床、组织病理学和分子特征:与典型胶质母细胞瘤的比较
该研究调查了2011至2020年间收治的成人IDH野生型胶质瘤患者,将具有小强化病灶且术前稳定超过1个月的病例定义为惰性弥漫性胶质瘤(iDGwt),并与癌症基因组图谱参考队列比较基因突变、拷贝数变化、MGMT启动子甲基化及生存数据。180例中9例(5.0%)符合iDGwt标准,其RB通路改变和EGFR扩增频率显著低于参考队列,总生存(中位37.5个月)显著长于参考队列(n=426,中位13.9个月)。结论认为iDGwt除PI3K/MAPK通路改变外缺乏胶质母细胞瘤的分子特征。
要点
- 180例IDH野生型胶质瘤中9例(5.0%)符合惰性弥漫性胶质瘤标准。
- iDGwt中RB通路改变频率显著低于参考队列(281/362例,77.6%)。
- iDGwt中EGFR扩增频率显著低于参考队列(412/426例,96.7%)。
核心结论
- iDGwt除PI3K/MAPK通路改变外缺乏胶质母细胞瘤的分子特征。
研究设计与样本
- 调查2011至2020年间收治的成人IDH野生型胶质瘤患者,临床惰性主要定义为具有小强化病灶且术前稳定超过1个月,采用现行WHO诊断标准,比较43个代表性胶质瘤相关基因的突变和拷贝数变化、MGMT启动子甲基化状态及生存数据与癌症基因组图谱参考队列。
主要发现
- 180例调查病例中9例(5.0%)符合iDGwt标准。
- 8例(88.9%)、4例(44.4%)、1例(11.1%)分别存在PI3K/MAPK、TP53、RB通路基因改变。
- RB通路改变频率显著低于参考队列(281/362例,77.6%)。
- 2例(22.2%)显示EGFR扩增并符合胶质母细胞瘤诊断标准,频率显著低于参考队列(412/426例,96.7%)。
- 本系列总生存(中位37.5个月)显著长于参考队列(n=426,中位13.9个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: IDH-wildtype (IDHwt) diffuse gliomas are treated as glioblastoma, however, some of these may show less aggressive clinical courses. The authors investigated the clinical, histopathological, and molecular characteristics of such IDHwt indolent diffuse gliomas (iDGwt), which have not been well documented in the literature. METHODS: Adult patients with IDHwt gliomas admitted between 2011 and 2020 were surveyed. In this particular study, the clinical indolence was defined mainly as having a small enhancing lesion and a stable period for more than 1 month before surgery. The current WHO diagnostic criteria were adapted for the diagnoses. Gene mutations and copy number changes in 43 representative glioma-associated genes, MGMT promoter methylation status, and survival data were compared with those of The Cancer Genome Atlas reference cohort. RESULTS: Nine out of 180 surveyed cases (5.0%) fulfilled the present criteria of the iDGwt. Considering the representative regulatory pathways, 8 (88.9%), 4 (44.4%), and 1 (11.1%) case had genetic alterations in the PI3K/MAPK, TP53, and RB pathways, respectively. The frequency of the RB pathway alteration was significantly lower than that in the reference cohort (281 of 362 cases: 77.6%). Two cases (22.2%) showing EGFR amplification met the diagnostic criteria for glioblastoma, and the frequency was significantly lower than that in the reference cohort (412 of 426 cases: 96.7%). The overall survival (median: 37.5 months) in the present series was significantly longer than that in the reference cohort (n = 426, median: 13.9 months). CONCLUSIONS: iDGwt lacked the molecular features of glioblastoma except for the PI3K/MAPK pathway alteration.
引用
- Suzuki H, Ono T, Koyota S, et al. Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma. J Neurooncol. 2022. PMID: 35779193. doi:10.1007/s11060-022-04074-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。